Neurothera Labs and Clearmind Medicine File Israeli Patent for Non-Hallucinogenic Depression Treatment

Neurothera Labs Inc., a clinical-stage biotech company and wholly-owned subsidiary of SciSparc Ltd., announced that Clearmind Medicine Inc. has filed an Israeli patent application for an innovative combination therapy of 5-methoxy-2-aminoindane (MEAI) and N-Acylethanolamines, such as Palmitoylethanolamide (PEA), targeting depression treatment. This patent application results from the ongoing collaboration between Neurothera and Clearmind Medicine Inc., marking another milestone in their joint efforts to develop novel therapeutics for mental health conditions.

The therapy addresses a critical global health need, as major depressive disorder affects more than 280 million people worldwide according to the World Health Organization and remains one of the leading causes of disability. Current treatment options for depression remain limited, with many patients experiencing inadequate response to existing medications or unacceptable side effects. The combination of MEAI and PEA represents a novel approach that could potentially offer improved efficacy and tolerability compared to conventional antidepressants.

This new filing further expands the joint intellectual property portfolio developed through the collaboration between Neurothera and Clearmind Medicine. To date, 13 patents have been filed under the partnership, focusing on MEAI and N-Acylethanolamines combinations for various conditions including alcohol use disorder, cocaine addiction, obesity and weight loss, and now depression. The growing portfolio demonstrates the companies' commitment to developing science-backed solutions for challenging mental health conditions through innovative drug combinations.

Preclinical data supports MEAI's efficacy in mitigating addictive behaviors while preserving normal natural reward pathways, suggesting potential advantages over existing treatments that may disrupt normal pleasure responses. The non-hallucinogenic nature of the treatment combination addresses concerns associated with psychedelic-based therapies currently under investigation for depression. This characteristic could make the therapy more suitable for widespread clinical use and potentially reduce the need for intensive medical supervision during treatment.

The collaboration between Neurothera and Clearmind Medicine represents a significant advancement in the field of neuroplastogen treatments, which aim to promote neural plasticity and repair in the brain. As the companies continue to advance MEAI-based treatments toward clinical development, this latest patent filing strengthens their intellectual property position in the competitive depression treatment market. Investors and stakeholders can find additional information about the companies' regulatory filings at https://www.sedarplus.ca, though the Company cautions that forward-looking statements involve uncertainties and patent applications may not necessarily result in issued patents.